Can You Give P-CAB 50mg Twice Daily?
No, you should not prescribe P-CAB (tegoprazan) 50mg twice daily as standard dosing—the approved and studied regimen is 50mg once daily for most acid-related conditions. The evidence does not support twice-daily dosing of tegoprazan 50mg for routine clinical use 1.
Standard Dosing for P-CABs
The 2024 AGA guidelines and clinical evidence establish that:
- Tegoprazan 50mg once daily is the standard therapeutic dose for acid-related disorders 2
- P-CABs have longer half-lives (6-9 hours) compared to PPIs (1-2 hours), which allows for once-daily dosing with sustained 24-hour acid suppression 1
- Unlike PPIs, P-CABs do not require meal-timed administration and achieve maximal acid suppression within 1 day (versus 3-5 days for PPIs) 1
When P-CABs Are Appropriate (at Standard Once-Daily Dosing)
According to the 2024 AGA Clinical Practice Update 1:
Should be used:
- H. pylori eradication (in place of PPIs for most patients)
- Severe erosive esophagitis (LA grade C/D) that has failed PPI therapy
May be used:
- Documented acid-related reflux failing twice-daily PPIs
- Selected patients with nonerosive GERD refractory to twice-daily PPIs
Should NOT be used as first-line:
- Mild erosive esophagitis (LA grade A/B)
- Uninvestigated heartburn or nonerosive GERD
- Peptic ulcer disease treatment or prophylaxis
- Non-erosive GERD without documented PPI failure
Clinical Context for Twice-Daily Dosing
The only scenario where twice-daily P-CAB dosing appears in the literature is for H. pylori eradication regimens, where tegoprazan 50mg twice daily was studied as part of combination therapy with antibiotics 3. However, even in this context:
- The eradication rate was 88.3% in per-protocol analysis
- Clarithromycin-resistant strains showed poor eradication (only 4/16 successful)
- This was part of a 7-day quadruple therapy with bismuth, not monotherapy
Important Caveats
Cost and access barriers: P-CABs in the United States are markedly more expensive than PPIs and often require prior authorization 1. Even modest clinical superiority may not justify routine use as first-line therapy given cost differentials.
Safety considerations: While generally well-tolerated, P-CABs cause higher serum gastrin elevations than PPIs and may carry similar infection risks (C. difficile, enteric infections) due to profound acid suppression 1.
Long-term data: P-CABs have less robust long-term safety data compared to PPIs, which should factor into prescribing decisions 1.
Bottom Line
Prescribe tegoprazan 50mg once daily, not twice daily, for approved indications. Reserve P-CABs for patients with severe erosive esophagitis failing PPI therapy, H. pylori eradication, or documented acid-related reflux refractory to twice-daily PPIs. The twice-daily dosing regimen lacks evidence for routine clinical use outside specific H. pylori eradication protocols 1, 3.